the evolution of her2-low-positive breast cancer as a clinical subtype
Published 1 year ago • 137 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
1:36
is her2-low a distinct subtype of breast cancer?
-
0:52
defining her2-low breast cancer as a clinical subtype
-
0:45
the evolution of her2-low breast cancer from primary to recurrence
-
6:51
adcs for her2 and her2-low breast cancer
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
-
1:09
the exciting new field of her2-low breast cancer
-
1:40
her2-low is not a distinct subtype in inflammatory breast cancer
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
1:17
clinical outcomes in women with metastatic her2-low breast cancer in the real world
-
0:46
biological behaviour of her2-low bc is dependent on hr expression
-
2:01
destiny-breast04: practice-changing results for her2-low breast cancer
-
1:45
the comprehensive genomic characterization of her2-low breast cancer
-
54:43
the science of her2-low breast cancer and implications for the pathology team
-
1:33
questions remaining in the field of her2-low breast cancer
-
1:25:22
a new view of the spectrum of her2 expression and significance of her2 low in breast cancer
-
1:42
her2dx and pcr in her2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
-
1:26
genomic and transcriptomic landscape of her2-low breast cancer
-
2:21
adcs for the treatment of her2-low breast cancer
-
4:12
clinical implications of ‘low’ her2 expression: 2023 best of breast conference